Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints

Autor: Patoulias, D. ⁎, Katsimardou, A., Kalogirou, M.-S., Zografou, I., Toumpourleka, M., Imprialos, K., Stavropoulos, K., Stergiou, I., Papadopoulos, C., Doumas, M.
Zdroj: In Diabetes & Metabolism September 2020 46(4):272-279
Databáze: ScienceDirect
Externí odkaz: